Finally, in 2021, the results of two phase I trials demonstrated this recapitulation human‐to‐human, with responders' stool reinvigorating anti‐PD1 response in a subset of melanoma patients with resistant or refractory tumours [94, 95]. The gene discussed is PDCD1; the disease is neoplasm.